Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Cornelia Liedtke"'
Autor:
A. Kohls, Hans-Peter Fischer, Ronald E. Kates, Matthias Christgen, Michael Braun, T. Reimer, Hans Heinrich Kreipe, Nadia Harbeck, Jochem Potenberg, Katja Krauss, E-M. Grischke, Andrea Stefek, Helmut Forstbauer, O Gluz, Doris Augustin, Ulrike Nitz, Claudia Schumacher, Johannes Schumacher, Cornelia Liedtke, Sherko Kuemmel, Rachel Wuerstlein
Publikováno v:
Annals of Oncology. 28:2768-2772
Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR- trial assessed whether patients with stro
Autor:
Birgit Pott, Markus Wallwiener, Johannes Ettl, Rüdiger Schulz-Wendtland, Leyla Akpolat-Basci, Erik Belleville, Alexander Hein, Diana Lüftner, Florin-Andrei Taran, Dirk Pott, Peyman Hadji, Wolfgang Janni, Hans Tesch, Naiba Nabieva, Andreas Schneeweiss, Hans-Christian Kolberg, Thomas Geyer, Hanna Einarson, Michael P. Lux, Bernhard Volz, Andreas D. Hartkopf, Michael Untch, Lothar Häberle, Cornelia Liedtke, Volkmar Müller, Sarah Wetzig, Peter A. Fasching, Harald Seeger, Diethelm Wallwiener, Sara Y. Brucker, Friedrich Overkamp, Arndt Hartmann, Matthias W. Beckmann, Tanja Fehm, Paul Gass
Publikováno v:
Breast cancer research and treatment. 173(2)
Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM).
Autor:
Hans-Christian Kolberg, Leyla Akpolat-Basci, Bahriye Aktas, Cornelia Liedtke, Carla Hannig, Miltiades Stephanou
Publikováno v:
Breast Care. 11:323-327
Introduction: Most patients with HER2-positive breast cancer receive chemotherapy and trastuzumab. Data from adjuvant trials have shown that the combination of docetaxel, carboplatin and weekly trastuzumab (TCH) is well tolerated and as effective as
Autor:
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Nikola Bangemann, Christoph Lindner, Sherko Kuemmel, Michael Clemens, Jochem Potenberg, Peter Staib, Andreas Kohls, Raquel von Schumann, Ronald Kates, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590677f09768f30013068e57eb5b3aae
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85053498560
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85053498560
Publikováno v:
Lancet (London, England). 389(10087)
Summary Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-neg
Autor:
Achim Rody, Cornelia Liedtke
Publikováno v:
Reviews on recent clinical trials. 12(2)
Patients with triple negative breast cancer (TNBC) are characterized by an unfavorable prognosis particularly when not responding well to anthracycline-taxane chemotherapy. This is due to a more aggressive biology in some cases but most importantly t
Publikováno v:
Reviews on recent clinical trials. 12(2)
Primary endocrine therapy is an option in cases of hormone receptor positive and HER2 negative non-metastatic breast cancer. Aromatase inhibitors are considered the therapy of choice in postmenopausal patients. In premenopausal patients aromatase inh
Autor:
Rachel Wuerstlein, Cornelia Liedtke, Michael Braun, U. Nitz, Astrid Kiermaier, Nadia Harbeck, J. Tio, H.H. Kreipe, Helmut Forstbauer, J. Potenberg, S. de Haas, Bahriye Aktas, Ronald E. Kates, Anke Kleine-Tebbe, O Gluz, Matthias Christgen, Doris Augustin, Claudia Schumacher, S. Kuemmel, Stefan Kraemer
Publikováno v:
Cancer Research. 76:S5-03
Background: In HER2+ early breast cancer (eBC) pCR rates after standard neoadjuvant chemo- + anti-HER2 therapy differ according to hormone-receptor (HR) status. Molecular analysis reveals HER2+/HR+ BC as a distinct entity within HER2+ BC. The ADAPT H